Zydus Lifesciences Ltd on Monday announced that it has received final approval from the US Food and Drug Administration (USFDA) for its generic Deflazacort oral suspension (22.75 mg/ml), used in the treatment of Duchenne Muscular Dystrophy (DMD) — a severe inherited muscular disorder.

The company stated in a regulatory filing that the approval allows it to market the product for use in patients aged five years and above.